Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.

Proceedings of the National Academy of Sciences of the United States of America - 22 Mar 2022

Kavran Andrew J, Stuart Scott A, Hayashi Kristyn R, Basken Joel M, Brandhuber Barbara J, Ahn Natalie G

Abstract excerpt

Patients with melanoma receiving drugs targeting BRAFV600E and mitogen-activated protein (MAP) kinase kinases 1 and 2 (MEK1/2) invariably develop resistance and face continued progression. Based on preclinical studies, intermittent treatment involving alternating periods of drug withdrawal and rechallenge has been proposed as a method to delay the onset of resistance. The beneficial effect of intermittent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Mitogen-Activated Protein Kinases

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 35290123
DOI: 10.1073/pnas.2113535119
PMCID: PMC8944661

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.PMID 35290123Read ↗

Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cellsSemantic proximity Read ↗

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.Semantic proximity Read ↗

Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant MelanomaSemantic proximity Read ↗

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.Semantic proximity Read ↗

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.Semantic proximity Read ↗

Nongenetic Mechanisms of Drug Resistance in MelanomaSemantic proximity Read ↗

Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.Semantic proximity Read ↗

Understanding the potential benefits of adaptive therapy for metastatic melanomaSemantic proximity Read ↗

Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistanceSemantic proximity Read ↗

Trametinib-Resistant Melanoma Cells Displaying MITFhigh/NGFRlow/IL-8low Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge.Semantic proximity Read ↗

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancerSemantic proximity Read ↗

Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.